Delving into NASDAQ:TGTX's Growth Prospects.

In this article we will dive into TG THERAPEUTICS INC (NASDAQ:TGTX) as a possible candidate for growth investing. Investors should always do their own research, but we noticed TG THERAPEUTICS INC showing up in our Louis Navellier growth screen, which makes it worth to investigate a bit more.

Why NASDAQ:TGTX may be interesting for growth investors.

• TG THERAPEUTICS INC demonstrates a strong Return on Equity(ROE) of 53.87%. This indicates the company's ability to generate favorable returns for shareholders and reflects its efficient utilization of capital. TG THERAPEUTICS INC shows promising potential for continued success.
• With a track record of beating EPS estimates 3 times in the last 4 quarters, TG THERAPEUTICS INC showcases its consistent ability to deliver earnings surprises. This reflects the company's strong execution and its competitive position in the market.
• TG THERAPEUTICS INC has demonstrated strong 1-year revenue growth of 1.0K%, reflecting revenue momentum and its ability to generate consistent top-line expansion. This growth underscores the company's strong market position and its potential for future success.
• TG THERAPEUTICS INC has achieved significant quarter-to-quarter (Q2Q) revenue growth of 357.0%, signaling its ability to capture market opportunities and drive top-line expansion. This growth underscores the company's effective execution and its potential for continued success.
• With positive growth in its operating margin over the past year, TG THERAPEUTICS INC showcases its ability to improve profitability through effective cost control and operational efficiency. This growth underscores the company's commitment to enhancing its financial performance.
• With positive growth in its free cash flow (FCF) over the past year, TG THERAPEUTICS INC showcases its ability to generate strong cash flows and maintain a solid financial position. This growth reflects the company's efficient utilization of capital and its commitment to long-term value creation.
• In the most recent financial report, TG THERAPEUTICS INC reported a 112.0% increase in quarterly earnings compared to the previous quarter. This notable growth indicates positive momentum in the company's financials, suggesting an upward trend
• Over the past 3 months, analysts have adjusted their EPS Estimate for TG THERAPEUTICS INC with a 329.0% change. This highlights the evolving outlook on the company's EPS potential.
• In the most recent financial report, TG THERAPEUTICS INC reported a 112.0% increase in quarterly earnings compared to the previous quarter. This notable growth indicates positive momentum in the company's financials, suggesting an upward trend
• TG THERAPEUTICS INC shows accelerating EPS growth: when comparing the current Q2Q growth of 112.0% to the previous year Q2Q growth of -13.33%, we see the growth rate improving.

What is the full fundamental picture of NASDAQ:TGTX telling us.

At ChartMill, a crucial aspect of their analysis is the assignment of a Fundamental Rating to each stock. This rating, ranging from 0 to 10, is calculated daily by considering numerous fundamental indicators and properties.

Overall TGTX gets a fundamental rating of 6 out of 10. We evaluated TGTX against 568 industry peers in the Biotechnology industry. While TGTX has a great health rating, its profitability is only average at the moment. TGTX is not overvalued while it is showing excellent growth. This is an interesting combination. This makes TGTX very considerable for growth investing!

Our latest full fundamental report of TGTX contains the most current fundamental analsysis.

More growth stocks can be found in our Lois Navellier screen.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.